MEP43608A - Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist - Google Patents

Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist

Info

Publication number
MEP43608A
MEP43608A MEP-436/08A MEP43608A MEP43608A ME P43608 A MEP43608 A ME P43608A ME P43608 A MEP43608 A ME P43608A ME P43608 A MEP43608 A ME P43608A
Authority
ME
Montenegro
Prior art keywords
sodium salt
telmisartan
crystalline sodium
same
angiotensin antagonist
Prior art date
Application number
MEP-436/08A
Other languages
English (en)
Croatian (hr)
Inventor
Kai Donsbach
Irmgard Hof
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7704331&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP43608(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of MEP43608A publication Critical patent/MEP43608A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MEP-436/08A 2001-10-31 2002-10-11 Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist MEP43608A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10153737A DE10153737A1 (de) 2001-10-31 2001-10-31 Kristallines Natriumsalz des Telmisartans, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
YUP-363/04A RS50879B (sr) 2001-10-31 2002-10-11 Kristalna natrijumova so telmisartana i njena primena kao angiotenzinskog antagonista
PCT/EP2002/011394 WO2003037876A1 (de) 2001-10-31 2002-10-11 Kristallines natriumsalz des telmisartans und dessen verwendung als angiotensin antagonist

Publications (1)

Publication Number Publication Date
MEP43608A true MEP43608A (en) 2011-02-10

Family

ID=7704331

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-436/08A MEP43608A (en) 2001-10-31 2002-10-11 Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist

Country Status (35)

Country Link
EP (1) EP1442023B1 (xx)
JP (1) JP5124076B2 (xx)
KR (1) KR100929502B1 (xx)
CN (1) CN100509789C (xx)
AR (1) AR037148A1 (xx)
AT (1) ATE370125T1 (xx)
AU (1) AU2002338886B2 (xx)
BR (1) BR0213568A (xx)
CA (1) CA2463146C (xx)
CO (1) CO5580785A2 (xx)
CY (1) CY1107504T1 (xx)
DE (2) DE10153737A1 (xx)
DK (1) DK1442023T3 (xx)
EA (1) EA007596B1 (xx)
EC (1) ECSP045089A (xx)
ES (1) ES2291505T3 (xx)
HK (1) HK1073841A1 (xx)
HR (1) HRPK20040372B3 (xx)
HU (1) HUP0402391A3 (xx)
IL (2) IL161165A0 (xx)
ME (1) MEP43608A (xx)
MX (1) MXPA04004013A (xx)
MY (1) MY129741A (xx)
NO (1) NO326465B1 (xx)
NZ (1) NZ532716A (xx)
PE (1) PE20030629A1 (xx)
PL (1) PL211462B1 (xx)
PT (1) PT1442023E (xx)
RS (1) RS50879B (xx)
SA (1) SA02230419B1 (xx)
SI (1) SI1442023T1 (xx)
TW (2) TWI333419B (xx)
UA (1) UA82833C2 (xx)
UY (1) UY27520A1 (xx)
WO (1) WO2003037876A1 (xx)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029363B2 (en) 2003-04-30 2015-05-12 Boehringer Ingelheim International Gmbh Telmisartan sodium salt pharmaceutical formulation
DE10319450A1 (de) * 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Formulierung des Telmisartan Natriumsalzes
WO2005077941A2 (en) 2004-02-11 2005-08-25 Teva Pharmaceutical Industries Ltd. Candesartan cilexetil polymorphs
MXPA06012702A (es) * 2004-05-05 2007-04-02 Teva Pharma Preparacion de candesartan cilexetil de alta pureza.
WO2006044754A2 (en) 2004-10-18 2006-04-27 Dr. Reddy's Laboratories Ltd. Process for preparing telmisartan
JP2008516001A (ja) * 2004-11-03 2008-05-15 テバ ファーマシューティカル インダストリーズ リミティド 非晶質、および多形のフォームのテルミサルタン・ナトリウム
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
EP2151450A1 (de) * 2008-07-29 2010-02-10 Sandoz AG Verfahren zur Aufarbeitung von mikrobiologisch hergestellten zyklischen Oligopeptiden
CN102458363A (zh) 2009-05-20 2012-05-16 贝林格尔.英格海姆维特梅迪卡有限公司 替米沙坦的药物口服溶液
EP2448576A2 (en) 2009-07-02 2012-05-09 Mahmut Bilgic Solubility enhancing pharmaceutical composition
EP2448575A2 (en) 2009-07-02 2012-05-09 Bilgic Mahmut Pharmaceutical composition increasing solubility and stability
EP2632438A1 (en) 2010-10-27 2013-09-04 KRKA, tovarna zdravil, d.d., Novo mesto Multilayer pharmaceutical composition comprising telmisartan and amlodipine
CN103619556B (zh) * 2011-06-24 2016-12-07 本田技研工业株式会社 注塑成形方法及其装置
MY197904A (en) 2011-11-25 2023-07-24 Adverio Pharma Gmbh Method for producing substituted 5-fluoro-1h-pyrazolopyridines
WO2016065028A1 (en) 2014-10-21 2016-04-28 Ariad Pharmaceuticals, Inc. Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] pyrimidine-2,4-diamine
KR101872726B1 (ko) * 2016-07-28 2018-06-29 주식회사 씨트리 텔미사르탄 메탄술폰산염 및 이를 포함하는 약제학적 조성물
DK3648761T3 (da) 2017-07-07 2024-06-24 Boehringer Ingelheim Vetmedica Gmbh Telmisartan til forebyggelsen eller behandlingen af hypertension i katte
JP2022517610A (ja) * 2019-01-10 2022-03-09 シーエスピーシー ゾンチー ファーマシューティカル テクノロジー(シージアチュアン)カンパニー,リミテッド 複素環化合物塩およびその使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI9210098B (sl) * 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5594003A (en) * 1991-02-06 1997-01-14 Dr. Karl Thomae Gmbh Tetrahydroimidazo[1,2-a]pyridin-2-yl-(benzimidazol-1-yl)-methyl-biphenyls useful as angiotensin-II antagonists
DE69718146T2 (de) * 1996-02-29 2003-10-02 Novartis Ag, Basel At1 rezeptor antagonist zur anregung von apoptosis
DE19901921C2 (de) * 1999-01-19 2001-01-04 Boehringer Ingelheim Pharma Polymorphe von Telmisartan, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung eines Arzneimittels

Also Published As

Publication number Publication date
TW201034664A (en) 2010-10-01
TW200300082A (en) 2003-05-16
CA2463146C (en) 2011-01-25
JP2005536445A (ja) 2005-12-02
TWI341200B (en) 2011-05-01
BR0213568A (pt) 2004-09-08
DE50210719D1 (de) 2007-09-27
UY27520A1 (es) 2003-05-30
SA02230419B1 (ar) 2007-07-31
KR100929502B1 (ko) 2009-12-03
DK1442023T3 (da) 2007-11-05
PL367477A1 (en) 2005-02-21
DE10153737A1 (de) 2003-05-28
EA007596B1 (ru) 2006-12-29
RS50879B (sr) 2010-08-31
SI1442023T1 (sl) 2007-12-31
CY1107504T1 (el) 2013-03-13
PL211462B1 (pl) 2012-05-31
AR037148A1 (es) 2004-10-27
PT1442023E (pt) 2007-09-17
CA2463146A1 (en) 2003-05-08
KR20050035172A (ko) 2005-04-15
ECSP045089A (es) 2004-06-28
NO20041758L (no) 2004-04-29
EA200400479A1 (ru) 2004-10-28
TWI333419B (en) 2010-11-21
CO5580785A2 (es) 2005-11-30
CN1578772A (zh) 2005-02-09
UA82833C2 (uk) 2008-05-26
IL161165A (en) 2009-12-24
HRP20040372A2 (en) 2004-10-31
MXPA04004013A (es) 2004-06-18
HK1073841A1 (en) 2005-10-21
ATE370125T1 (de) 2007-09-15
HRPK20040372B3 (en) 2006-02-28
EP1442023A1 (de) 2004-08-04
YU36304A (sh) 2006-08-17
AU2002338886B2 (en) 2008-04-17
PE20030629A1 (es) 2003-07-14
NZ532716A (en) 2007-06-29
CN100509789C (zh) 2009-07-08
JP5124076B2 (ja) 2013-01-23
EP1442023B1 (de) 2007-08-15
HUP0402391A3 (en) 2010-03-29
NO326465B1 (no) 2008-12-08
MY129741A (en) 2007-04-30
IL161165A0 (en) 2004-08-31
HUP0402391A2 (hu) 2005-03-29
ES2291505T3 (es) 2008-03-01
WO2003037876A1 (de) 2003-05-08

Similar Documents

Publication Publication Date Title
MEP43608A (en) Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist
TW200509914A (en) Pharmaceutical formulation of the telmisartan sodium salt
YU51101A (sh) Polimorfni oblici telmisartana, postupak za njihovo pripremanje i njihova primena za pripremanje leka
UA106199C2 (ru) Производные аминобензамида как агенты, пригодные для использования для борьбы с паразитами животных
HRP20040996B1 (en) High drug load tablet
MX365986B (es) Derivativos de piperidina fusionados con espiro para usarse como inhibidores del canal de potasio medular externo renal.
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
PT1204650E (pt) Compostos de 2-arilbenzazole substituido e sua utilizacao como agentes antitumorais.
DK1458393T3 (da) Substituerede diketopiperaziner som oxytocinantagonister
ATE537249T1 (de) Wiedergewinnung von gewebefunktion nach verabreichung von b-zellen an verletztes gewebe
BR0313173A (pt) preparação farmacêutica que contém um composto de benzimidazol misto com celulose microcristalina, método para sua preparação, bem como uso da dita celulose microcristalina
ES2195010T3 (es) Derivados de di-arilalquenilaminas.
EA200500687A1 (ru) Применение дистронциевой соли 2-[n,n-ди(карбоксиметил)амино]-3-циано-4-карбоксиметилтиофен-5-карбоновой кислоты при получении лекарственных средств, предназначенных для лечения гастродуоденальной боли
PE20010621A1 (es) Derivados de bencimidazol sustituidos, procedimiento para su preparacion y su empleo como medicamentos
BR0307039A (pt) Compostos, em particular de derivados uréias ou ésteres do ácido haloacetamidobenzóico e sua utilização para o tratamento de doenças parasitárias
ECSP078024A (es) Inhibidores de la adenilato ciclasa soluble
DK1155014T3 (da) Hidtil ukendte benzimidazolforbindelser til anvendelse som aktive, terapeutiske stoffer, fremgangsmåde til fremstilling af disse forbindelser og farmaceutiske sammensætninger omfattende dem
PE20010622A1 (es) Derivados de bencimidazol, sustituidos con arilsulfonamida, procedimiento para su preparacion y su empleo como medicamentos
TH60890A (th) ผลึกเกลือโซเดียมของเทลมิซาร์แทน และการใช้สารที่เหมือนกันเป็นแองจิโอเทนซิน แอนทาโกนิสท์
ECSP993250A (es) Polimorfos de telmisartan, procedimiento para su preparacion y su empleo para la preparacion de un medicamento
AR038711A1 (es) Elementos traza: una solucion y un bloque para lamedero de ganado